Qin Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qin Han has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
- Robert Chunhua Zhao
School of Life Sciences Shanghai University Shanghai China
24 shared publications - Zhao Sun
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
13 shared publications Xuechun Li
Department of Stomatology Center, Xiangya Hospital, Central South University, Changsha, China
10 shared publications- Chunmei Bai
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
8 shared publications Zhao Sun
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, PekingBeijing, China
7 shared publicationsChunling Xue
Beijing Key Laboratory, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Center of Excellence in Tissue Engineering Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
6 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 5101
Mesenchymal Stem Cells Attenuate Diabetic Nephropathy by Suppressing the ERK-Ferroptosis-ROS Axis
Diabetic nephropathy (DN) is a leading cause of end-stage renal disease with limited therapeutic options. Ferroptosis contributes to renal tubular injury in DN. This study investigates whether mesenchymal stem cells (MSCs) ameliorate DN by inhibiting ferroptosis and elucidates the underlying mechanism. In a rat model of type 2 DN, MSCs transplantation improved renal function and histopathology, while reducing mitochondrial dysfunction, iron overload, and ROS-driven ferroptosis. In vitro, MSCs reversed high glucose-induced ferroptosis hallmarks in tubular epithelial cells. Mechanistically, RNA sequencing identified the MAPK/ERK pathway as key. MSCs suppressed the p-ERK/ERK-GPX4/ACSL4 axis, preventing glutathione depletion and lipid peroxidation. Activation of ERK abolished MSCs’ protection, whereas ERK inhibition mimicked it. These findings reveal that targeting ERK-mediated ferroptosis in renal tubules offers a novel therapeutic strategy, with MSCs acting through this specific mechanism.
- 4 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 5101
Open AccessMesenchymal Stem Cells Attenuate Diabetic Nephropathy by Suppressing the ERK-Ferroptosis-ROS Axis
Diabetic nephropathy (DN) is a leading cause of end-stage renal disease with limited therapeutic options. Ferroptosis contributes to renal tubular injury in DN. This study investigates whether mesenchymal stem cells (MSCs) ameliorate DN by inhibiting ferroptosis and elucidates the underlying mechanism. In a rat model of type 2 DN, MSCs transplantation improved renal function and histopathology, while reducing mitochondrial dysfunction, iron overload, and ROS-driven ferroptosis. In vitro, MSCs reversed high glucose-induced ferroptosis hallmarks in tubular epithelial cells. Mechanistically, RNA sequencing identified the MAPK/ERK pathway as key. MSCs suppressed the p-ERK/ERK-GPX4/ACSL4 axis, preventing glutathione depletion and lipid peroxidation. Activation of ERK abolished MSCs’ protection, whereas ERK inhibition mimicked it. These findings reveal that targeting ERK-mediated ferroptosis in renal tubules offers a novel therapeutic strategy, with MSCs acting through this specific mechanism.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S21 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Figure S1. AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S2. Dual-AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S3. Quality control of the APCM CRISPR activation screen in the E0771 lung metastasis model. Figure S4. AAV-mediated ORF delivery of immunostimulatory factors elicited antitumor responses. Figure S5. Validation of the six-gene combination CLCG4I in the E0771 metastatic tumor model. Figure S6. Evaluation of IL-12 and IL-23 formation in vitro and in vivo following AAVIL12B treatment. Figure S7. Safety evaluation of AAV-4II treatment. Figure S8. AAV-mediated ORF delivery of immunostimulatory molecules promotes immune cell infiltration into the TME. Figure S9. Gating strategy for analyzing tumor-infiltrating immune cell populations. Figure S10. Comparison of pathway enrichment for the bulk RNA-seq data for tumor cells. Figure S11. Comparison of pathway enrichment in tumor cells between AAV-4II and IFNG from the bulk RNA-seq dataset. Figure S12. Comparative transcriptomic analysis of tumor-infiltrating OT-I T cells across AAV treatment groups. Figure S13. Single-cell transcriptomic profiling reveals 4II-induced transcriptional reprogramming of lung-infiltrating T cells. Figure S14. Cell-cell communication and ligand-receptor interaction analysis in AAV-4II treated tumors. Figure S15. CCL and CXCL signaling pathway network following AAV-4II treatment. Figure S16. Ectopic expression of immunostimulatory factors synergizes with human CART cells. Figure S17. Combining AAV-4II with CAR-T cell enhances anti-tumor activity in human tumor models. Figure S18. Signature gene expression in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S19. Differential pathways in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S20. Elevated 4II signature expression is associated with immunotherapy response. Figure S21. Impact of 4II gene signatures on human patient survival in cancer immunotherapy treatment settings.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S21 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Figure S1. AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S2. Dual-AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S3. Quality control of the APCM CRISPR activation screen in the E0771 lung metastasis model. Figure S4. AAV-mediated ORF delivery of immunostimulatory factors elicited antitumor responses. Figure S5. Validation of the six-gene combination CLCG4I in the E0771 metastatic tumor model. Figure S6. Evaluation of IL-12 and IL-23 formation in vitro and in vivo following AAVIL12B treatment. Figure S7. Safety evaluation of AAV-4II treatment. Figure S8. AAV-mediated ORF delivery of immunostimulatory molecules promotes immune cell infiltration into the TME. Figure S9. Gating strategy for analyzing tumor-infiltrating immune cell populations. Figure S10. Comparison of pathway enrichment for the bulk RNA-seq data for tumor cells. Figure S11. Comparison of pathway enrichment in tumor cells between AAV-4II and IFNG from the bulk RNA-seq dataset. Figure S12. Comparative transcriptomic analysis of tumor-infiltrating OT-I T cells across AAV treatment groups. Figure S13. Single-cell transcriptomic profiling reveals 4II-induced transcriptional reprogramming of lung-infiltrating T cells. Figure S14. Cell-cell communication and ligand-receptor interaction analysis in AAV-4II treated tumors. Figure S15. CCL and CXCL signaling pathway network following AAV-4II treatment. Figure S16. Ectopic expression of immunostimulatory factors synergizes with human CART cells. Figure S17. Combining AAV-4II with CAR-T cell enhances anti-tumor activity in human tumor models. Figure S18. Signature gene expression in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S19. Differential pathways in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S20. Elevated 4II signature expression is associated with immunotherapy response. Figure S21. Impact of 4II gene signatures on human patient survival in cancer immunotherapy treatment settings.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors.Significance:By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors.Significance:By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Next-generation sequencing datasets, including CRISPR screens, bulk RNA-seq, single-cell RNA-seq, and datasets related to adoptive cell therapy (ACT) and immune checkpoint blockade (ICB).
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Next-generation sequencing datasets, including CRISPR screens, bulk RNA-seq, single-cell RNA-seq, and datasets related to adoptive cell therapy (ACT) and immune checkpoint blockade (ICB).
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Source data and statistical analyses for in vivo and in vitro experiments.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Source data and statistical analyses for in vivo and in vitro experiments.
- 27 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (6) , 1222-1244
Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors. Significance: By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- 27 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (6) , 1222-1244
Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors. Significance: By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- Open Access
- 23 October 2025
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 42 (10)
TUBB3 (βIII-tubulin) drives gastric cancer progression and poor prognosis by regulating cell cycle and invadopodia formation
Background: Gastric cancer is the fifth most common malignancy and third leading cause of cancer death in China, with advanced-stage five-year survival below 20%. βIII-tubulin (TUBB3) is overexpressed in cancers but its role in gastric cancer remains unclear. Methods: TUBB3 expression was analyzed using TCGA data and clinical samples. Knockdown models assessed its effects on proliferation, migration, and invasion in vitro and in vivo. Results: TUBB3 was significantly upregulated in gastric cancer tissues versus normal mucosa. High TUBB3 correlated with poorer disease-free and overall survival but not other clinicopathological features. Functionally, TUBB3 knockdown inhibited proliferation via G2/M arrest and reduced migration/invasion by disrupting invadopodia, without affecting apoptosis, EMT, or ECM degradation. In vivo, TUBB3 depletion suppressed tumor growth and metastasis. Mechanistically, TUBB3 promoted G2/M transition via p21/Cyclin B1 and enhanced invasiveness through Cortactin/JNK activation. Conclusion: TUBB3 overexpression predicts poor prognosis in gastric cancer. It drives proliferation via cell cycle regulation and metastasis through invadopodia formation, suggesting its potential as a therapeutic target.
- 23 October 2025
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 42 (10)
Open AccessTUBB3 (βIII-tubulin) drives gastric cancer progression and poor prognosis by regulating cell cycle and invadopodia formation
Background: Gastric cancer is the fifth most common malignancy and third leading cause of cancer death in China, with advanced-stage five-year survival below 20%. βIII-tubulin (TUBB3) is overexpressed in cancers but its role in gastric cancer remains unclear. Methods: TUBB3 expression was analyzed using TCGA data and clinical samples. Knockdown models assessed its effects on proliferation, migration, and invasion in vitro and in vivo. Results: TUBB3 was significantly upregulated in gastric cancer tissues versus normal mucosa. High TUBB3 correlated with poorer disease-free and overall survival but not other clinicopathological features. Functionally, TUBB3 knockdown inhibited proliferation via G2/M arrest and reduced migration/invasion by disrupting invadopodia, without affecting apoptosis, EMT, or ECM degradation. In vivo, TUBB3 depletion suppressed tumor growth and metastasis. Mechanistically, TUBB3 promoted G2/M transition via p21/Cyclin B1 and enhanced invasiveness through Cortactin/JNK activation. Conclusion: TUBB3 overexpression predicts poor prognosis in gastric cancer. It drives proliferation via cell cycle regulation and metastasis through invadopodia formation, suggesting its potential as a therapeutic target.
- Open Access
- 21 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e010812
Autophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC
Background: Cancer-associated fibroblasts (CAFs) are major non-tumor cellular components of the tumor microenvironment (TME) and are closely related to immune suppression. The enhancement of anti-programmed cell death protein-1 (PD-1) efficacy by antiangiogenic tyrosine kinase receptor inhibitors (TKIs) is partly due to the elimination of CAFs, which improves the immunosuppressive microenvironment. However, it remains unclear whether antiangiogenic TKIs regulate the autophagy of CAFs, thereby affecting the immunotherapy response. Methods: We first examined the effects of autophagy inhibition and anlotinib on the TME and immunotherapy response via animal experiments. Then, CAF models were established in vitro. The effects and mechanisms of autophagy inhibition on the efficacy of anlotinib and CAFs were further explored in vitro. To specifically validate the role of CAF autophagy, we additionally constructed LLC tumor-bearing mouse models co-implanted with CAFs transfected with ATG5-targeting siRNA or non-targeting control siRNA. Results: In anti-PD-1-resistant (LLC) and CAF-rich (LA795+MSC) non-small cell lung cancer models, the autophagy inhibitor chloroquine significantly enhanced anlotinib+anti-PD-1 efficacy—likely by inducing more apoptosis of CAFs and M2 macrophages, reshaping the TME to promote CD8+T cell infiltration. After ATG5 knockdown (autophagy inhibition) in CAFs, the efficacy-enhancing effect of anti-PD-1 therapy was significantly attenuated versus control, confirming CAF autophagy is core to TME regulation. In vitro, anlotinib induced CAF autophagy via AKT/mTOR inhibition; inhibiting CAF autophagy enhanced anlotinib-induced CAF apoptosis and impaired CAFs’ ability to recruit M2 macrophages. Conclusions: Autophagy inhibition enhances the effects of antiangiogenic TKIs on tumor cells and CAFs and directly or indirectly regulates the TME, which might explain why autophagy inhibition enhances the efficacy of antiangiogenic TKIs combined with anti-PD-1 therapy.
- 21 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e010812
Open AccessAutophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC
Background: Cancer-associated fibroblasts (CAFs) are major non-tumor cellular components of the tumor microenvironment (TME) and are closely related to immune suppression. The enhancement of anti-programmed cell death protein-1 (PD-1) efficacy by antiangiogenic tyrosine kinase receptor inhibitors (TKIs) is partly due to the elimination of CAFs, which improves the immunosuppressive microenvironment. However, it remains unclear whether antiangiogenic TKIs regulate the autophagy of CAFs, thereby affecting the immunotherapy response. Methods: We first examined the effects of autophagy inhibition and anlotinib on the TME and immunotherapy response via animal experiments. Then, CAF models were established in vitro. The effects and mechanisms of autophagy inhibition on the efficacy of anlotinib and CAFs were further explored in vitro. To specifically validate the role of CAF autophagy, we additionally constructed LLC tumor-bearing mouse models co-implanted with CAFs transfected with ATG5-targeting siRNA or non-targeting control siRNA. Results: In anti-PD-1-resistant (LLC) and CAF-rich (LA795+MSC) non-small cell lung cancer models, the autophagy inhibitor chloroquine significantly enhanced anlotinib+anti-PD-1 efficacy—likely by inducing more apoptosis of CAFs and M2 macrophages, reshaping the TME to promote CD8+T cell infiltration. After ATG5 knockdown (autophagy inhibition) in CAFs, the efficacy-enhancing effect of anti-PD-1 therapy was significantly attenuated versus control, confirming CAF autophagy is core to TME regulation. In vitro, anlotinib induced CAF autophagy via AKT/mTOR inhibition; inhibiting CAF autophagy enhanced anlotinib-induced CAF apoptosis and impaired CAFs’ ability to recruit M2 macrophages. Conclusions: Autophagy inhibition enhances the effects of antiangiogenic TKIs on tumor cells and CAFs and directly or indirectly regulates the TME, which might explain why autophagy inhibition enhances the efficacy of antiangiogenic TKIs combined with anti-PD-1 therapy.
- 9 January 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (1) , 293-302
Mechanism of female CHH caused by compound heterozygous mutations in the LHB gene
Background Luteinizing hormone (LH) plays a crucial role in the postnatal development and maturation of gonads. Inactivating mutations of the luteinizing hormone beta subunit (LHB)gene are extremely rare and can result in congenital hypogonadotropic hypogonadism (CHH). Methods We conducted DNA sequencing on an 18-year-old female patient with undetectable LH and clinical symptoms of CHH. Pulsatile GnRH was administered to promote puberty development. In vitro construction of mutant genes, confocal microscopy, and protein functional assays were used to investigate the effects of genetic variants on hormone function and secretion. Experiments were conducted in HEK293T cells to examine the colocalization and dimerization of LH subunits, as well as to measure intracellular and extracellular LH concentrations. Results Compound heterozygous mutations of c.252C>G (p.F84L) and c.364G>A (p.G122S) were found in the patient’s genome. Pulsatile GnRH therapy was effective in promoting puberty development and ovulation. The LH alpha subunit was found to co-localize with both mutant beta subunits after immunofluorescence staining, and immunoprecipitation detected the dimerization of the LH alpha subunit with both mutant beta subunits. Higher intracellular LH concentrations and lower extracellular LH concentrations compared to the wild type indicate secretion dysfunction for LH. Conclusion Compound heterozygous mutations of c.252C>G (p.F84L) and c.364G>A (p.G122S) in the LHB gene may lead to CHH for female patient. These mutations do not impair the expression and dimerization of the alpha and beta subunits, but they do prevent the secretion of LH. The study expands our understanding of the clinical manifestation of LHB gene mutations in females and provides a treatment for these patients.
- 9 January 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (1) , 293-302
Mechanism of female CHH caused by compound heterozygous mutations in the LHB gene
Background Luteinizing hormone (LH) plays a crucial role in the postnatal development and maturation of gonads. Inactivating mutations of the luteinizing hormone beta subunit (LHB)gene are extremely rare and can result in congenital hypogonadotropic hypogonadism (CHH). Methods We conducted DNA sequencing on an 18-year-old female patient with undetectable LH and clinical symptoms of CHH. Pulsatile GnRH was administered to promote puberty development. In vitro construction of mutant genes, confocal microscopy, and protein functional assays were used to investigate the effects of genetic variants on hormone function and secretion. Experiments were conducted in HEK293T cells to examine the colocalization and dimerization of LH subunits, as well as to measure intracellular and extracellular LH concentrations. Results Compound heterozygous mutations of c.252C>G (p.F84L) and c.364G>A (p.G122S) were found in the patient’s genome. Pulsatile GnRH therapy was effective in promoting puberty development and ovulation. The LH alpha subunit was found to co-localize with both mutant beta subunits after immunofluorescence staining, and immunoprecipitation detected the dimerization of the LH alpha subunit with both mutant beta subunits. Higher intracellular LH concentrations and lower extracellular LH concentrations compared to the wild type indicate secretion dysfunction for LH. Conclusion Compound heterozygous mutations of c.252C>G (p.F84L) and c.364G>A (p.G122S) in the LHB gene may lead to CHH for female patient. These mutations do not impair the expression and dimerization of the alpha and beta subunits, but they do prevent the secretion of LH. The study expands our understanding of the clinical manifestation of LHB gene mutations in females and provides a treatment for these patients.
- 24 December 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (1) , 1-16
Molecular intersections of traumatic brain injury and Alzheimer’s disease: the role of ADMSC-derived exosomes and hub genes in microglial polarization
Traumatic brain injury (TBI) is a significant contributor to global mortality and morbidity, with emerging evidence indicating a heightened risk of developing Alzheimer’s disease (AD) following TBI. This study aimed to explore the molecular intersections between TBI and AD, focusing on the role of adipose mesenchymal stem cell (ADMSC)-derived exosomes and hub genes involved in microglial polarization. Transcriptome profiles from TBI (GSE58485) and AD (GSE74614) datasets were analyzed to identify differentially expressed genes (DEGs). The hub genes were validated in independent datasets (GSE180811 for TBI and GSE135999 for AD) and localized to specific cell types using single-cell RNA (scRNA) sequencing data (GSE160763 for TBI and GSE224398 for AD). Experimental validation was conducted to investigate the role of these genes in microglial polarization using cell culture and ADMSC-derived exosomes interventions. Our results identified three hub genes—Bst2, B2m, and Lgals3bp—that were upregulated in both TBI and AD, with strong associations to inflammation, neuronal apoptosis, and tissue repair processes. scRNA sequencing revealed that these genes are predominantly expressed in microglia, with increased expression during M1 polarization. Knockdown of these genes reduced M1 polarization and promoted M2 phenotype in microglia. Additionally, ADMSC-derived exosomes attenuated M1 polarization and downregulated the expression of hub genes. This study provides novel insights into the shared molecular pathways between TBI and AD, highlighting potential therapeutic targets for mitigating neuroinflammation and promoting recovery in both conditions.
- 24 December 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (1) , 1-16
Molecular intersections of traumatic brain injury and Alzheimer’s disease: the role of ADMSC-derived exosomes and hub genes in microglial polarization
Traumatic brain injury (TBI) is a significant contributor to global mortality and morbidity, with emerging evidence indicating a heightened risk of developing Alzheimer’s disease (AD) following TBI. This study aimed to explore the molecular intersections between TBI and AD, focusing on the role of adipose mesenchymal stem cell (ADMSC)-derived exosomes and hub genes involved in microglial polarization. Transcriptome profiles from TBI (GSE58485) and AD (GSE74614) datasets were analyzed to identify differentially expressed genes (DEGs). The hub genes were validated in independent datasets (GSE180811 for TBI and GSE135999 for AD) and localized to specific cell types using single-cell RNA (scRNA) sequencing data (GSE160763 for TBI and GSE224398 for AD). Experimental validation was conducted to investigate the role of these genes in microglial polarization using cell culture and ADMSC-derived exosomes interventions. Our results identified three hub genes—Bst2, B2m, and Lgals3bp—that were upregulated in both TBI and AD, with strong associations to inflammation, neuronal apoptosis, and tissue repair processes. scRNA sequencing revealed that these genes are predominantly expressed in microglia, with increased expression during M1 polarization. Knockdown of these genes reduced M1 polarization and promoted M2 phenotype in microglia. Additionally, ADMSC-derived exosomes attenuated M1 polarization and downregulated the expression of hub genes. This study provides novel insights into the shared molecular pathways between TBI and AD, highlighting potential therapeutic targets for mitigating neuroinflammation and promoting recovery in both conditions.